CAR-T in the Treatment of Acute Myeloid Leukemia: Barriers and How to Overcome Them
Open Access
- 18 August 2023
- journal article
- review article
- Published by Wiley in HemaSphere
- Vol. 7 (9) , e937
Abstract
Conventional therapies for acute myeloid leukemia (AML) are characterized by high rates of relapse, severe toxicities, and poor overall survival rates. Thus, the development of new therapeutic strategies is crucial for improving the survival and quality of life of AML patients. CD19-directed chimeric antigen receptor (CAR) T-cell immunotherapy has been extremely successful in the treatment of B-cell acute lymphoid leukemia and several mature B-cell lymphomas. However, the use of CAR T-cell therapy for AML is currently prevented due to the lack of a myeloid equivalent to CD19, as currently known cell surface targets on leukemic blasts are also expressed on healthy hematopoietic stem and progenitor cells as well as their progeny. In addition, the immunosuppressive tumor microenvironment has a dampening effect on the antitumor activity of CAR-T cells. Here, we review the therapeutic challenges limiting the use of CAR T-cell therapy for AML and discuss promising novel strategies to overcome them.Keywords
This publication has 94 references indexed in Scilit:
- The Cancer Genome Atlas Pan-Cancer analysis projectNature Genetics, 2013
- Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironmentBlood, 2013
- T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in HumansCancer Immunology Research, 2013
- Interleukin 15 Provides Relief to CTLs from Regulatory T Cell–Mediated Inhibition: Implications for Adoptive T Cell–Based Therapies for LymphomaClinical Cancer Research, 2013
- Mutated regions of nucleophosmin 1 elicit both CD4+ and CD8+ T-cell responses in patients with acute myeloid leukemiaBlood, 2012
- Lck is a key target of imatinib and dasatinib in T-cell activationLeukemia, 2010
- T lymphocyte chemotactic chemokines in acute myelogenous leukemia (AML): local release by native human AML blasts and systemic levels of CXCL10 (IP-10), CCL5 (RANTES) and CCL17 (TARC)Cancer Immunology, Immunotherapy, 2005
- An inducible caspase 9 safety switch for T-cell therapyBlood, 2005
- Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemiaLeukemia, 2004
- Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptorNature Biotechnology, 2002